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Abstract
Background: The largest single cause of death among people with severe mental disorders is cardiovascular
disease (CVD). The majority of people with schizophrenia and bipolar disorder smoke and many are also
overweight, considerably increasing their risk of CVD. Treatment for smoking and other health risk behaviours is
often not prioritized among people with severe mental disorders. This protocol describes a study in which we will
assess the effectiveness of a healthy lifestyle intervention on smoking and CVD risk and associated health
behaviours among people with severe mental disorders.
Methods/Design: 250 smokers with a severe mental disorder will be recruited. After completion of a baseline
assessment and an initial face-to-face intervention session, participants will be randomly assigned to either a multi-
component intervention for smoking cessation and CVD risk reduction or a telephone-based minimal intervention
focusing on smoking cessation. Randomisation will be stratified by site (Newcastle, Sydney, Melbourne, Australia),
Body Mass Index (BMI) category (normal, overweight, obese) and type of antipsychotic medication (typical,
atypical). Participants will receive 8 weekly, 3 fortnightly and 6 monthly sessions delivered face to face (typically 1
hour) or by telephone (typically 10 minutes). Assessments will be conducted by research staff blind to treatment
allocation at baseline, 15 weeks, and 12-, 18-, 24-, 30- and 36-months.
Discussion: This study will provide comprehensive data on the effect of a healthy lifestyle intervention on smoking
and CVD risk among people with severe mental disorders. If shown to be effective, this intervention can be
disseminated to treating clinicians using the treatment manuals.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR) identifier: ACTRN12609001039279
Background
Cardiovascular disease (CVD) is the largest single cause
of death among people with schizophrenia [1] and bipo-
lar disorder [2]. The majority of people with schizophre-
nia and bipolar disorder smoke [3], considerably
increasing their risk of CVD. Many also suffer from obe-
sity, related to inactivity, unhealthy diets and some psy-
chiatric medications [4]. Despite increasing recognition
of the widespread impact that smoking and other
unhealthy behaviours have on increased morbidity and
mortality, treatment is often neglected among people
with severe mental disorders. This randomised con-
trolled trial of a Healthy Lifestyles intervention is the
first of its kind to address these issues by employing a
multi-component healthy lifestyle intervention for smok-
ing and CVD risk behaviours among people with severe
mental disorders.
The Healthy Lifestyles intervention was evaluated in a
pilot program [5] which showed that setting a variety of
goals, and assisting clients to make small steps towards
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change unhealthy lifestyle behaviour. In that study we
developed and piloted a multi-component Healthy Life-
styles intervention aimed at CVD risk reduction and
smoking cessation among 43 smokers with severe men-
tal disorders. Primary dependent variables were CVD
risk score and smoking. Secondary dependent variables
included weight, physical activity, unhealthy eating, sub-
stance use, psychiatric symptomatology, treatment
retention, general functioning, and quality of life. Signifi-
cant improvements in the primary dependent variables,
CVD risk and smoking, and secondary dependent vari-
ables, weight and physical activity were found. There
was also an improvement in diet although this did not
reach statistical significance. The results of the pilot
study suggested that the CVD risk factor intervention
was feasible and effective in significantly reducing CVD
risk and smoking among people with severe mental
disorders. Excellent retention rates (84% completed all
sessions), especially among males, attested to the impor-
tance and relevance of the intervention for people with
psychosis. Participant reports indicated high levels of
satisfaction with the program content, with access to
nicotine replacement therapy (NRT) that was tailored to
their needs, and with the opportunity to target a range
of lifestyle factors that they considered important, but
had hitherto been neglected. Many participants felt that
they would have benefited from a longer intervention to
provide scope to modify all the lifestyle issues targeted
by the treatment and to consolidate gains. Other
research [6] has reported that extended counselling can
be significantly more effective than standard treatment,
among depressed smokers. Consequently, we embarked
upon the current larger-scale randomised controlled
trial, with a longer treatment period; it is funded by
competitive research grants from the National Health
and Medical Research Council of Australia (project IDs
569210 and APP1009351). This trial is registered with
the Australian New Zealand Clinical Trials Registry
(ACTRN12609001039279).
Methods/Design
Study aims
The purpose of the research described here is to test the
effectiveness of a multi-component intervention for
smoking cessation and CVD risk reduction among peo-
ple with severe mental disorders. It is hypothesised that
the intervention will produce greater, more sustainable
improvements in CVD risk and smoking status relative
to the control condition at follow-up.
Study design & setting
This is a prospective randomised controlled comparison
study. Figure 1 shows the overall design. After completion
of a baseline assessment and an initial face-to-face
intervention session, participants will be randomly
assigned to either a multi-component intervention for
smoking cessation and CVD risk reduction or a tele-
phone-based minimal intervention focusing on smoking
cessation. Randomisation will be stratified by site (New-
castle, Sydney, Melbourne, Australia), Body Mass Index
(BMI) category (normal, overweight: ≥ 25 and < 30;
obese: ≥ 30) and type of antipsychotic medication (typi-
cal, atypical). A permuted block randomisation approach
will be used so that the distribution of participants
across treatment conditions will be maintained regard-
less of the final sample size. Following completion of the
baseline assessment for each participant, the clinicians
will be issued with a sealed randomisation envelope (by
an independent person) which displays the participant
identification code. The envelope will be opened by the
participant at the conclusion of the initial session. This
research will be conducted in three sites: Centre for
Brain and Mental Health Research, University of New-
castle, New South Wales (NSW); School of Public
Health, University of NSW, Sydney, NSW; and the Mon-
ash Alfred Psychiatry Research Centre (MAPrc), Mon-
ash University and The Alfred, Melbourne, Victoria,
Australia. The researchers involved are experienced clin-
icians and scientists. Ethical approval was obtained for
t h i ss t u d yt h r o u g ht h el e a ds i t eo fH u n t e rN e wE n g l a n d
Human Ethics Committee and at each site.
Patients
Approximately 250 smokers with a severe mental disor-
der will be identified from community mental health
services, outpatient hospital clinics, psychology and gen-
eral practices or using self-referral from the general
community (e.g. via media advertisements). Written,
informed consent will be obtained from each potential
volunteer before baseline assessment.
Inclusion Criteria
1) Age 18 years and over (minimum age level recom-
mended for the use of nicotine replacement therapy,
NRT);
2) Diagnosis of a severe mental disorder, as confirmed
by the Mini International Neuropsychiatric Interview
(MINI; [7]) - schizophrenia spectrum or bipolar
disorder;
3) Current smoker (at least 15 cigarettes per day); and
4) Taking antipsychotic medication as prescribed for a
period of at least two months, with intention to con-
tinue for the duration of the study.
Exclusion Criteria
1) Non-English speakers;
2) Organic brain diseases; and
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(NRT or overall, e.g. uncontrolled diabetes, pregnancy).
Participants will be permitted to access additional treat-
ments outside the proposed study, including psychiatric
medication: any such treatments will be recorded at
each assessment occasion. Any person who indicates
suicidal ideation will be assessed using a standard sui-
cide checklist. Only those persons judged as serious risk
for suicide will have their participation suspended and
be referred to the relevant psychiatric service. The same
protocol will be used for people experiencing an acute
phase of their psychotic disorder at any stage in the
treatment program.
Content of the Interventions
Treatment, including NRT, will be provided free to all
participants across the face-to-face and phone-based
conditions to assist with their attempts at tobacco absti-
nence and/or reduction. As stated above, all participants
will receive an identical first session, after which they
will receive four of the 24 weeks supply of NRT. The
remaining NRT will be given to participants at weeks 4,
8 and 15. The NRT protocol is flexible and has been
described elsewhere [8]. Briefly, participants smoking at
least 30 cigarettes per day are eligible to receive double
patching in addition to up to 12 × 2 mg lozenges per
day, with NRT tapering occurring over the last month
of delivery.
Therapists will be psychologists and both the active and
control interventions will be guided by manuals (which
are available upon request: Baker AL, Kay-Lambkin FJ,
Geddes J, Beck A, Sakrouge R, Filia S, Turner A, Clark V:
Healthy Lifestyles intervention therapist manual and
Healthy Lifestyles intervention telephone manual.
Unpublished manuscripts: University of Newcastle; 2010).
Participants will be asked to provide details of their gen-
eral practitioner (GP), psychiatrist and case worker and
to consent to the therapist liaising with these profes-
sionals regarding assessment results and treatment pro-
gress, management of any acute episodes, and arranging
follow-up.
The initial session before randomisation will be con-
ducted face to face with the therapist and will focus on
providing feedback to participants regarding their smok-
ing (e.g. level of dependence) and other risk factors for
CVD. A case formulation will be developed with the

Recruit participants across 3 sites 


Baseline Assessment 


1-session of feedback and randomisation 









Control 
7 x weekly phone check-in + NRT 
3 x fortnightly phone check-in + NRT 
6 x monthly phone check-in + NRT 
15-wk assessment (independent assessor) 
Healthy Lifestyles Treatment 
7 x weekly sessions of CBT + NRT 
3 x fortnightly sessions of CBT + NRT 
6 x monthly sessions of CBT + NRT 
15-wk assessment (independent assessor) 
12-, 18-, 24-, 30-, and 36-month 
assessments (independent assessor) 
12-, 18-, 24-, 30-, and 36-month 
assessments (independent assessor) 
Figure 1 Study Design.
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behaviours, with motivational interviewing (MI) being
conducted to help the person consider changes in risk
behaviours.
Healthy Lifestyles Therapist Delivered Intervention (active
treatment)
The active treatment protocol focuses on the adoption
of more healthy lifestyle choices (see [8] for session by
session summary). The initial session will be of 90 min-
utes duration, followed by seven one hour weekly ses-
sions, three fortnightly hour long sessions and then
monthly sessions of one hour duration for six months.
A harm reduction focus is an important factor in the
engagement and retention of participants, who may pre-
sent with a range of preparedness to change the lifestyle
factors currently impacting on their health and well-
being. The intervention is designed to encourage smok-
ing cessation and improvements in diet and physical
activity, using a combination of MI and cognitive beha-
viour therapy (CBT) techniques. The initial focus of
treatment will be based on the particular CVD risk fac-
tor(s), in addition to smoking, considered most proble-
matic by the participant. Therapists will integrate
messages and skill development about other CVD risk
factors opportunistically. Self-help material will be pro-
vided throughout the treatment period, according to the
CVD risk factors being discussed in each session.
Smoking cessation component
In addition to the provision of NRT that is common to
both the Healthy Lifestyle therapist and phone-based
conditions, the intervention includes education about
the interaction between nicotine and symptomatology,
medication and cognition, options for NRT, and exam-
ining beliefs regarding the relationship between smoking
and symptoms. Despite a harm reduction focus, cessa-
tion as the ultimate goal will be encouraged for all parti-
cipants, and a supportive follow-up telephone call will
be made 2-3 days following the initial quit attempt [9].
Nicotine withdrawal symptom severity, cravings to
smoke and adverse medication side-effects will be moni-
tored each session.
Contingency reinforcement component
In the face-to-face condition, contingent reinforcement
will be utilised, as it has been identified as an effective
technique for facilitating smoking cessation amongst
individuals with severe mental illness [10]. Expired car-
bon monoxide (CO) will be monitored each week, with
positive reinforcement provided in the form of certifi-
cates and financial reimbursement (cash and vouchers)
when participants meet predetermined criteria for suc-
cess. The contingency reinforcement schedule will be
based on a shaping model. Relative to an abstinent-only
model, a shaping model rewards participants for
successive reductions in CO readings as well as absti-
nence. This is in accordance with both abstinence and
harm reduction approaches to substance use change.
There are several components to this model. Firstly, ses-
sion-by-session reimbursement is contingent upon
demonstrated reductions in expired CO (explained in
detail below). Secondly, participants receive a bonus
once they meet the CO criterion for a given (set) num-
ber of consecutive weeks (e.g. three weeks in a row).
Thirdly, an additional ‘bonus’ is on offer every week for
participants who demonstrate abstinence (< 10 ppm
expired CO). An advantage of this schedule is that it
accounts for individual differences in baseline CO and
rates of behaviour change. However, it is anticipated
that many participants will be approaching and/or have
met the abstinence criterion by the end of the weekly
phase of treatment. As such, during the fortnightly and
monthly sessions, reinforcement will be contingent upon
abstinence only (<10 ppm expired CO). In summary, we
will adopt a shaping schedule during the weekly phase
of treatment whilst the fortnightly and monthly sessions
will provide positive reinforcement only for abstinence.
Physical activity component
This component will be integrated with the other com-
ponents of the Healthy Lifestyles intervention. Specific
strategies will be introduced in session 4, with discus-
sion of ways to increase levels of physical activity in
everyday life (e.g. taking the stairs rather than the lift)
and introduction of a graded walking program with pro-
vision of pedometers. Daily pedometer readings have
been incorporated into participant monitoring forms,
and will also be used to provide objective feedback to
treating therapists about the extent of this activity in the
day prior to each treatment session. Should participants
express a desire to work on their physical activity earlier
than session 4, then these strategies will be brought for-
ward in the treatment sequence as required.
Dietary and nutrition component
This component will be integrated with the above
Healthy Lifestyles strategies with an emphasis on
increasing healthy food choices rather than on an ‘ideal’
caloric intake. Healthy eating habits will initially be dis-
cussed in session 7, with food planning and goal setting
following in session 8. Specific motivational and CBT-
related techniques will include encouraging participants
to eat a variety of foods, eating foods that are high in
fibre and low in fat, trying to eat five or more servings
of fruits and vegetables a day and drinking plenty of
water each day, eating regularly, and drinking alcohol
within the recommended guidelines for Australia. Parti-
cipants will be encouraged to consider issues that
prevent them from making healthy choices (such as
‘non-hungry eating’, eating on a budget, cost effective
meal plans and planning a shopping list). Finally,
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nutrient interactions and tips for dealing with medica-
tion side effects. As with physical activity, nutritional
strategies will be brought forward to earlier sessions in
the treatment program should participants wish to focus
on these issues prior to session 7.
Booster sessions
Participants will receive six monthly booster sessions,
during which a range of issues can be discussed. These
sessions will include relapse prevention, overcoming
lapses, review of previous sessions, methods to promote
and maintain changes, and NRT tapering.
Monitoring
During each treatment session of the Healthy Lifestyle
intervention, participants and therapists will complete
the following range of formal measurements: side-effects
from medication, nicotine withdrawal, weight, cigarettes
per day, expired carbon monoxide (CO), NRT use over
the past week, and average minutes walking continu-
ously and briskly per week (based on physical activity
diary entries).
Phone-based Condition (control)
In order to orient participants to possible lifestyle
changes and in particular, NRT use, those in the phone-
based condition will receive an individual 90 minute
face-to-face session a week following baseline assessment,
as described above. To control for the number of thera-
pist contacts, brief, manualised telephone calls (around
10 minutes) will be conducted with participants in this
condition, to ‘check in’ about smoking and NRT use.
Therapists will complete the following formal assess-
ments for each phone session: adverse symptom checklist
(antipsychotic medication), nicotine withdrawal and cur-
rent symptoms of psychosis and mood. Self-report mea-
surements of cigarettes per day, exercise and dietary
intake will be taken each week during the phone-based
sessions. These phone-based sessions will be made at the
same intervals as therapist visits for the Healthy Lifestyles
intervention condition (i.e. weekly for eight weeks, fort-
nightly for three sessions, followed by monthly calls for
six months). In place of the phone-based sessions at
weeks 4 and 8, participants will attend face to face ses-
sions of 30 minutes duration where NRT is dispensed,
and where any problems with NRT or symptomatology
are monitored. Biomedical measures (expired CO and
weight) will also be taken at these two sessions.
Treatment Fidelity
Throughout the treatment period, all staff will receive
regular weekly clinical supervision. Treatment fidelity
will be monitored by delivering the therapy in a consis-
tent fashion, closely adhering to the Healthy Lifestyles
and phone-based (control) manuals. In addition, all
treatment sessions will be audio recorded. An indepen-
dent assessor will randomly select a 20% sample of tapes
for each therapist, and rate tapes for treatment fidelity.
Therapists will also be asked to bring along taped treat-
ment sessions to clinical supervision sessions for discus-
sion among the group.
Outcome Measures
Outcome measures will be performed at baseline, during
treatment (week 15), and at 12-, 18-, 24-, 30- and
36-months after baseline. Baseline assessments will be
conducted prior to notification of randomisation status.
Post-treatment and follow-up assessments will be con-
ducted by independent assessors who will remain blind
to intervention allocation.
All assessment instruments are widely used in mental
health and/or tobacco treatment research and practice
(see Table 1), and cover the domains hypothesised to be
impacted upon by the treatment. CO measures will be
taken one hour after arrival to partially control for
effects of travelling in traffic, etc. Each participant will
be offered up to $20AUD for each assessment, as reim-
bursement for their out of pocket expenses (e.g. travel).
As in the pilot study, the two primary outcome vari-
ables will be: (i) overall CVD risk index for participants;
and (ii) smoking status; while the secondary dependent
variables will include: weight; physical activity; unhealthy
eating; substance use; psychiatric symptomatology; treat-
ment retention and treatment alliance; service utilisa-
tion; general functioning; and quality of life. The CVD
risk index calculation will be performed using the
National Vascular Disease Prevention Alliance Absolute
Risk Assessment [11] which is based on the Framing-
ham algorithms [12]. Within this index, multiple risk
factors of age, gender, systolic blood pressure, cigarette
smoking, cholesterol and diabetes are used to predict
CVD risk over 5 years [11]. Blood pressure measure-
ments will be taken, as well as a small blood sample by
finger prick to measure cholesterol and blood glucose
levels. A general health and well-being questionnaire
will also be completed by participants to identify lifestyle
habits and previous medical history. Smoking status will
be determined according to point prevalence abstinence
(last 7 days) and continuous abstinence (since quit
attempt), both of which will be biochemically validated
by a CO reading of ≤10 ppm. Additionally, we will use
50% reduction in cigarettes per day as an indicator of
smoking status [13].
We also plan to report the cost of delivering the inter-
vention in real world settings and the cost impacts of
the outcomes achieved by calibration of selected instru-
ments used in the study (e.g. Quality of Life Scale, Glo-
bal Assessment of Functioning) with those achieved in
other costing studies.
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Prior research conducted by the authors indicates that
attrition rates for CBT trials with this sample are, on
average, 18% over a 12-month study period following
treatment. Thus at 24-month follow-up in the current
study (approximately 12 months following the end of
treatment), 205 participants will likely remain in the
study (102 per treatment condition). Regular contact at
every 6 month interval until 36 months post baseline is
likely to retain this sample size. This will provide suffi-
cient statistical power (80%) to detect moderate popula-
tion differences of the order of 0.5 of a standard
deviation, using conventional 0.01 level, 2-tailed tests for
the primary variables of interest. This is the equivalent
of a differential change of approximately 7 cigarettes per
day or 13 points on the 100 point CVD risk score, both
moderate but clinically useful differences.
Statistical Analysis
Data coding and analysis will be carried out by the
authors using available software packages (e.g. Statistical
Package for Social Sciences for Windows). Variables
hypothesised to change over time according to treatment
allocation will be examined predominantly using general-
ized linear mixed models, techniques that facilitate man-
agement of missing data without imputing values or
excluding participants. Chi-square analyses or binary
logistic regressions will be performed on categorical out-
come variables. Primary outcome measures will typically
be analysed in two ways: (1) intention to treat (with study
dropouts regarded as continuing smokers and/or with
unchanged CVD risk relative to baseline); and (2) ana-
lyses performed within the sub-sample of participants
who completed the majority of treatment sessions. In
addition, comparisons on selected demographic and
Table 1 Assessment instruments proposed for the current study
Instrument Initial 15-wk 12-, 18-, 24-, 30- 36-months
Tobacco Use
Opiate Treatment Index (OTI, quantity/frequency) [14] √√ √
Point Prevalence and Continuous Abstinence √√ √
Readiness to Quit Smoking [15] √ --
Fagerstrom Test for Nicotine Dependence [16] √√ √
Expired Carbon Monoxide √√ √
Minnesota Nicotine Withdrawal Scale (MNWS-R) [17] √√ √
Physical Activity
Readiness to change physical activity [18] √ --
Physical activity screen (past week) √√ √
Average minutes walking per week √√ √
International Physical Activity Questionnaire [19] √√ √
Dietary Habits
Readiness to change eating habits √ --
24-hour recall of eating patterns √√ √
Other CVD Risk Factors
OTI- alcohol and cannabis √√ √
Beck Depression Inventory - II [20] √√ √
Brief Symptom Inventory [21] √√ √
Body mass index (height, weight) √√ √
Waist-hip ratio (cms) √√ √
Auscultatory Blood pressure √√ √
Fingerprick Blood Tests (glucose, cholesterol, lipids) √√ √
Treatment and Service Utilisation [22] √√ √
Diagnosis of psychosis and Symptom Measure
Brief Psychiatric Rating Scale [23] √√ √
Mini International Neuropsychiatric Interview [22] √ --
Functioning
Global Assessment of Functioning [24] √√ √
Medical Outcome Survey SF-36 [25] √√ √
Quality of Life Scale [26] √√ √
Impact of Weight on Quality of Life Questionnaire [27] √√ √
Therapeutic Alliance & Intervention Satisfaction [28] - √ -
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sample and those who dropped out of treatment, to help
detect any biases in outcome measures. Other potential
confounders will also be examined (e.g. involvement in
additional treatments) and their potential effects mod-
elled in the major analyses (e.g., controlling and not con-
trolling for these variables). As a partial control for the
number of statistical tests, the threshold for significance
will be set at p < 0.01.
Discussion
There have been several challenging operational issues
in mounting the present trial, which fall into two broad
categories: delivering the intended interventions; and
recruiting and retaining participants.
Intervention delivery
T h em u l t i - s i t en a t u r eo ft h et r i a lh a sr e q u i r e dc l o s e
attention to staff training and supervision. All therapists
have prior experience working with people with mental
disorders. Manuals for the therapist and telephone deliv-
ered conditions are used to guide therapists in each ses-
sion and detailed protocols have been written for NRT
and contingency management components of the inter-
vention. The lead investigator (AB) has trained clinical
staff at each site and conducts ongoing weekly group
telephone supervision with the therapists. Face to face
supervision is also provided separately at each site, with
a focus on feedback regarding audiotaped sessions.
Therapists usually have to travel to community centres
providing mental health treatment, requiring travel time
and expenses. While the multi-component nature of the
interventions, and our tolerance for additional treat-
ments (outside of the study) are both positive design
features, and reflect real-world treatment contexts, they
also reduce our capacity to assess the contributions of
specific intervention components (or, alternatively,
necessitate larger sample sizes, to ensure sufficient num-
bers of participants who have undertaken particular life-
style changes).
Recruitment and retention
Recruiting participants with a severe mental disorder
who are prepared to change aspects of their lifestyle
requires persistence and flexibility. On the one hand,
recruitment into the study has at times been slower
than anticipated, with some services referring relatively
few people. On the other hand, the stringent entry cri-
teria (e.g., smoking at least 15 cigarettes per day) has
meant that some volunteers were necessarily excluded
from the study. The assessment battery for the study
has been divided into two one and a half hour sessions,
due to its length and the need to complete self-report
instruments with participants. Engagement in treatment
is enhanced by flexible treatment goals and treatment
has occasionally been temporarily suspended whilst par-
ticipants are admitted to hospital or become too unwell
to engage in the interventions. Some participants who
have poor literacy skills have also been assisted by modi-
fication of self-monitoring sheets to include pictures. As
the maintenance of behaviour change is of crucial inter-
est, booster sessions and longer-term assessments are
highly desirable. Fortunately, additional funding from
the National Health and Medical Research Council of
Australia has been successfully sought for follow-up
over three years.
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